Evidence map›Paper›PMID 42812730›Full record

ArticleCureus2026

Patterns and Frequency of Opioid Use Among Individuals With a History of Gastrointestinal Malignancy: A Cross-Sectional Analysis of the 2019-2020 National Health Interview Survey (NHIS).

Mohammed D Al-Hejaili, Rami Saleh, Ghazi H Mogharbel, Dana F Maufa, Abdulmohsen Hassan, Maisa Manfaluti, Rifq S Altamimi, Linah A Murtadha, Abdulrahman I Almarwani, Renad K Alandejane

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammed D Al-HejailiAnesthesiology, National Guard Health Affairs, Medina, SAU.
Rami SalehAnesthesiology, National Guard Health Affairs, Medina, SAU.
Ghazi H MogharbelInternal Medicine, National Guard Health Affairs, Medina, SAU.
Dana F MaufaCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU.
Abdulmohsen HassanCollege of Medicine, University of Jeddah, Jeddah, SAU.
Maisa ManfalutiCollege of Pharmacy, Taibah University, Medina, SAU.
Rifq S AltamimiCollege of Medicine, Taibah University, Medina, SAU.
Linah A MurtadhaCollege of Pharmacy, Taibah University, Medina, SAU.
Abdulrahman I AlmarwaniCollege of Medicine, Alrayan Colleges, Medina, SAU.
Renad K AlandejaneCollege of Pharmacy, Taibah University, Medina, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Pain is a common symptom among individuals with gastrointestinal (GI) malignancies; yet, opioid use patterns and frequency remain understudied. Our study aims to characterize the frequency and patterns of opioid use among individuals with a history of GI malignancy diagnoses. Methods This study is a retrospective analysis of cross-sectional data from the 2019 and 2020 National Health Interview Survey (NHIS). A total of 594 adults with a previous diagnosis of GI cancer, namely, esophageal, stomach, pancreatic, liver, gallbladder, or colorectal cancers, were identified. Of these, 536 reported prescription medication use in the past 12 months and constituted the analytic population for opioid-use outcomes. Multivariate regression analysis with adjustment for sociodemographic and clinical covariates was used to identify factors associated with opioid use within the GI cancer cohort. As a secondary exploratory analysis using a different reference population (absence of each cancer type in the full cancer-history sample), we compared opioid use across all reported malignancy subtypes. Results Opioid use was reported by 143 out of the 536 respondents with a history of GI malignancy, who used prescription medications (26.67%), were younger (66.44 vs. 73.31 years, p<0.001), and were more likely to be smokers (87 (60.8%) vs. 193 (49.1%), p=0.02) compared with non-users. Among chronic users, 37 (46.6%) individuals reported daily use of opioids. Those with liver cancer and esophageal cancer had the highest rates of opioid use in the past 12 months (42.8% and 39.9%) and the lowest with colorectal malignancy (20.7%). Younger age and smoking history were independently associated with opioid use (adjusted odds ratio (aOR) 0.95 and aOR 1.61, respectively). Liver cancer (aOR 0.42) and colorectal cancer (aOR 0.52) were associated with lower odds of opioid use relative to other GI malignancy subtypes. In a separate exploratory model comparing opioid use across all reported cancer diagnoses, liver and esophageal cancers showed the strongest associations with opioid use (aOR 3.10 and aOR 2.85, respectively). Conclusion Opioid use is prevalent among GI cancer survivors and varies by malignancy subtype, with individuals diagnosed with esophageal and liver cancer showing the strongest association with opioid use, supporting consideration of cancer subtype-specific pain management strategies.

Indexed as

cancercancer-related paingastrointestinal cancergastrointestinal malignancyopioid use

Identifiers

PMID42812730
PMCPMC13621435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.